The Leadership Quarterly has retracted a trio of papers by Frederick Walumbwa, an “ethical leadership” guru at Florida International University, whose work has come under scrutiny for flawed methodology. And another journal has pulled one of his articles for similar reasons. That brings his count – as far as we can tell — to seven retractions and a mega-correction.
Meanwhile, Arizona State University, Walumbwa’s former employer, has found
that the preponderance of evidence does not support the charge of research misconduct by Dr. Walumbwa…
but that he engaged in “poor research practice.”
The bottom line, according to the Leadership Quarterly, which first announced problems with the articles in February:
Former University of Tokyo researcher Shigeaki Kato has notched his 26th, 27th, and 28th retractions, all in Nature Cell Biology. The three papers have been cited a total of 677 times.
Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg
Update, 4 p.m. EST, 10/29/14: As a commenter points out, we didn’t quite get this one right. The Boldt paper that has been retracted was not previously retracted for lack of IRB approval. Rather, it was a heretofore unretracted article, from 1996, which German investigators have determined contained faked data. We’ve made edits below using strikethroughs, and have changed the headline to better reflect the content. We apologize for the errors.
We’ve commented before on the fact that we’ve noticed there’s often more to retractions whose stated reason is lack of institutional review board (IRB) approval. We can understand editors’ inclination to act as quickly as possible to issue a retraction, the scientific publishing equivalent of jailing Al Capone for tax evasion. But we appreciate it even more when said editors return to the scene of the crime, as it were, when new important details come out.
Case in point: Anesthesia & Analgesia has amended its retraction of a 2009 1996 study by Joachim Boldt — who with nearly 90 retractions once held the record in that department — based on findings that the data in that paper were fabricated.
The article was titled “Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy,” “The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patient.” had previously been retracted because Boldt had failed to obtain adequate ethics approval for the research. But now comes this, According to the retraction notice from editor in chief Steven Shafer: Continue reading Boldt’s data were fake in 1996 paper
Last month, we reported that a Wayne State University cancer researcher had threatened legal action involving post-publication peer review site PubPeer, claiming that he had lost a job offer from the University of Mississippi because of comments on the site.
Gizem Donmez, a neuroscientist who has retracted two papers from Cell and the Journal of Biological Chemistry, is no longer in her position at Tufts University, Retraction Watch has learned.
Ulrich Lichtenthaler, a management professor at the University of Mannheim who has had to retract 16 papers for data irregularities, has resigned his faculty position.
A third study of GcMAF, a protein being used to treat a variety of conditions from AIDS to autism to cancer, all without the blessing of health agencies, has been retracted.
Phyllis Wise, the chancellor of the University of Illinois and an obstetrics researcher, has called for a massive correction of a 2006 paper in Neuroscience for work she appears to have tried to pass off as having been previously unpublished — but which wasn’t.
The article, “Estrogen therapy: Does it help or hurt the adult and aging brain? Insights derived from animal models,” has been cited 47 times, according to Thomson Scientific’s Web of Knowledge.
According to the NRC Handelsblad, Stapel resigned from the job at Fontys in solidarity with Anton Dautzenberg, whose contract at Fontys was terminated and with whom Stapel had co-authored a play. A performance of that play was cancelled last month.
